The Therapeutic Role of NPS-1034 in Pancreatic Ductal Adenocarcinoma as Monotherapy and in Combination with Chemotherapy
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25136919 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Yu-Ze Luan und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Apoptosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Chung Shan Medical University Hospital, Chung Shan Medical University Hospital Research Program, Taichung, Taiwan.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) poses a significant challenge in terms of diagnosis and treatment, with limited therapeutic options and a poor prognosis. This study explored the potential therapeutic role of NPS-1034, a kinase inhibitor targeting MET and AXL, in PDAC. The investigation included monotherapy with NPS-1034 and its combination with the commonly prescribed chemotherapy agents, fluorouracil and oxaliplatin. Our study revealed that NPS-1034 induces cell death and reduces the viability and clonogenicity of PDAC cells in a dose-dependent manner. Furthermore, NPS-1034 inhibits the migration of PDAC cells by suppressing MET/PI3K/AKT axis-induced epithelial-to-mesenchymal transition (EMT). The combination of NPS-1034 with fluorouracil or oxaliplatin demonstrated a synergistic effect, significantly reducing cell viability and inducing tumor cell apoptosis compared to monotherapies. Mechanistic insights provided by next-generation sequencing indicated that NPS-1034 modulates immune responses by inducing type I interferon and tumor necrosis factor production in PDAC cells. This suggests a broader role for NPS-1034 beyond MET and AXL inhibition, positioning it as a potential immunity modulator. Overall, these findings highlight the anticancer potential of NPS-1034 in PDAC treatment in vitro, both as a monotherapy and in combination with traditional chemotherapy, offering a promising avenue for further in vivo investigation before clinical exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.
- Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
- Department of Urology, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.
ORCID-Profile: Ya-Chuan Chang, Wen-Wei Sung
Förderung
- National Science and Technology Council
- Chung Shan Medical University Hospital
- Chung Shan Medical University Hospital Research Program, Taichung, Taiwan
Zitieren
APA
Luan, Y. Z., Wang, C. C., Yu, C. Y., Chang, Y. C., Sung, W. W., & Tsai, M. C. (2024). The Therapeutic Role of NPS-1034 in Pancreatic Ductal Adenocarcinoma as Monotherapy and in Combination with Chemotherapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25136919
Vancouver
Luan YZ, Wang CC, Yu CY, Chang YC, Sung WW, Tsai MC. The Therapeutic Role of NPS-1034 in Pancreatic Ductal Adenocarcinoma as Monotherapy and in Combination with Chemotherapy. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25136919
BibTeX
@article{Luan2024,
author = {Luan, Yu-Ze and Wang, Chi-Chih and Yu, Chia-Ying and Chang, Ya-Chuan and Sung, Wen-Wei and Tsai, Ming-Chang},
title = {The Therapeutic Role of NPS-1034 in Pancreatic Ductal Adenocarcinoma as Monotherapy and in Combination with Chemotherapy},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25136919}
}
EUVIMED